We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Liver Carcinogenesis Suppression in Chronic Hepatitis B in the Nucleoside Analogues Era.
- Authors
HIROKI NISHIKAWA; SOO KI KIM; AKIRA ASAI
- Abstract
There is a strong association between the distribution of Hepatitis B virus (HBV) carriers and the incidence of hepatocellular carcinoma (HCC). About 60% of HCC in Japan is caused by viral hepatitis. Ten to 15 percent of hepatitis virus-related HCCs derive from HBV. Recently, antiviral therapy against HBV has developed, and interferon therapy and nucleos(t)ide analogues (NAs) are currently the standard of care. NAs exhibit antiviral activity by inhibiting DNA polymerase and suppressing HBV replication. NAs are highly effective in suppressing HBV-DNA and improving alanine aminotransferase. The long-term treatment goal for chronic hepatitis B is HB surface antigen (HBsAg) loss. However, the number of patients who achieve HBsAg loss by NA (i.e., functional cure) is low and there have been cases of HCC incidence during (or after) NA therapy. In this article, we review the efficacy of NA therapy in suppressing HBV-derived carcinogenesis.
- Subjects
LIVER cancer; CHRONIC hepatitis B; NUCLEOSIDES; VIRAL antigens; TREATMENT effectiveness
- Publication
In Vivo, 2024, Vol 38, Issue 1, p40
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.13408